<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CEFOXITIN- cefoxitin sodiumÂ injection, powder, for solutionÂ </strong><br>West-ward Pharmaceutical Corp<br></p></div>
<h1>CEFOXITIN FOR INJECTION, USP<br><br><br>PHARMACY BULK PACKAGE<br>NOT FOR DIRECT INFUSION</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9346ec4e-d471-b822-c0c2-f911c3e70e4b"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefoxitin for injectionÂ and other antibacterial drugs, cefoxitin for injection should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_9e078f1b-8b0c-0bb5-ae9d-9e08369d81a9"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Cefoxitin for injection is a semi-synthetic, broad-spectrum cepha antibiotic sealed under nitrogen for intravenous administration. It is derived from cephamycinÂ C, which is produced by <span class="Italics">Streptomyces lactamdurans. </span>Its chemical name is sodium (6<span class="Italics">R</span>,7<span class="Italics">S</span>)-3-(hydroxymethyl)-7-methoxy-8-oxo-7-[2-(2-thienyl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate carbamate (ester). The molecular formula is C<span class="Sub">16</span>H<span class="Sub">16</span>N<span class="Sub">3</span>NaO<span class="Sub">7</span>S<span class="Sub">2</span>, and the structural formula is:</p>
<p>Â Â Â <img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6a4a2afa-4f00-41d4-bd6d-baa0a95f6929&amp;name=cefoxitin-injection-pbp-1.jpg">Â </p>
<p>Cefoxitin for injection contains approximately 53.8Â mg (2.3 milliequivalents) of sodium per gram of cefoxitin activity.Â Sterile Cefoxitin for Injection, USP is a dry white to off-white powder. Solutions of cefoxitinÂ for injection range from colorless to light amber in color. The pH of freshly constituted sollutions usually range from 4.2 to 7.0</p>
<p>Each Pharmacy Bulk Package Bottle of cefoxitinÂ for injection, USP is supplied as a dry powder and contains cefoxitin sodium equivalent to 10 grams of cefoxitin.</p>
<p>This Pharmacy Bulk Package Bottle is a container of sterile preparation for intravenous use that contains many single doses. The contents are intended for use in a pharmacy admixture service and are restricted to the preparation of admixtures for intravenous infusion. AFTER RECONSTITUTION FURTHER DILUTION IS REQUIRED BEFORE USE. NOT FOR DIRECT INFUSION.Â </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_4bcc12d3-53d6-de4e-d971-7752e9e5ed39"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_a16963da-47a6-fb4c-814d-3b80a019e15b"></a><a name="section-3.1"></a><p></p>
<h2>Clinical Pharmacology</h2>
<p class="First">Following an intravenous dose of 1Â gram, serum concentrations were 110Â mcg/mL at 5Â minutes, declining to less than 1Â mcg/mL at 4Â hours. The half-life after an intravenous dose is 41 to 59Â minutes. Approximately 85 percent of cefoxitin is excreted unchanged by the kidneys over a 6-hour period, resulting in high urinary concentrations. Probenecid slows tubular excretion and produces higher serum levels and increases the duration of measurable serum concentrations.</p>
<p>Cefoxitin passes into pleural and joint fluids and is detectable in antibacterial concentrations in bile.</p>
<p>In a published study of geriatric patients ranging in age from 64 to 88 years with normal renal function for their age (creatinine clearance ranging from 31.5 to 174.0 mL/min), the half-life for cefoxitin ranged from 51 to 90 minutes, resulting in higher plasma concentrations than in younger adults. These changes were attributed to decreased renal function associated with the aging process.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ed8b866f-ce9d-6c3a-b42c-115e9e842da9"></a><a name="section-3.2"></a><p></p>
<h2>Microbiology</h2>
<p class="First">The bactericidal action of cefoxitin results from inhibition of cell wall synthesis. Cefoxitin has <span class="Italics">in vitro</span> activity against a wide range of gram-positive and gram-negative organisms. The methoxy group in the 7Î± position provides cefoxitin with a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases, of gram-negative bacteria. </p>
<p>Cefoxitin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <a href="#LINK_e700b01e-ccd1-353f-31af-e7682c0755d2">INDICATIONS AND USAGE</a> section.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9974fdd8-367e-644a-aa5f-6357868654e2"></a><a name="section-3.2.1"></a><p></p>
<h3>Aerobic gram-positive microorganisms</h3>
<p class="First"><span class="Italics">Â Staphylococcus aureus</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a>(including penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><span class="Italics">Â Staphylococcus epidermidis<a href="#footnote-1" class="Sup">1</a></span></p>
<p><span class="Italics">Â Streptococcus agalactiae</span></p>
<p><span class="Italics">Â Streptococcus pneumoniae </span></p>
<p><span class="Italics">Â Streptococcus pyogenes</span></p>
<p>Â Most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of enterococci, e.g., <span class="Italics">Enterococcus faecalis </span>, are resistant.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd><p class="First">Staphylococci resistant to methicillin/oxacillin should be considered resistant to cefoxitin.</p></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b16de27a-37c6-934d-eb66-a33bdad1be5d"></a><a name="section-3.2.2"></a><p></p>
<h3>Aerobic gram-negative microorganisms</h3>
<p class="First"><span class="Italics">Â Escherichia coli</span></p>
<p><span class="Italics">Â Haemophilus influenzae</span></p>
<p><span class="Italics">Â Klebsiella</span> spp. (including <span class="Italics">K.Â pneumoniae</span>)</p>
<p><span class="Italics">Â Morganella morganii</span></p>
<p><span class="Italics">Â Neisseria gonorrhoeae </span>(including penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><span class="Italics">Â Proteus mirabilis</span></p>
<p><span class="Italics">Â Proteus vulgaris</span></p>
<p><span class="Italics">Â Providencia</span> spp. (including <span class="Italics">Providencia rettgeri</span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_55cbee39-a898-022c-9c40-b3aad663041e"></a><a name="section-3.2.3"></a><p></p>
<h3>Anaerobic gram-positive microorganisms</h3>
<p class="First"><span class="Italics">Â Clostridium </span>spp.</p>
<p><span class="Italics">Â Peptococcus</span>Â <span class="Italics">niger</span></p>
<p><span class="Italics">Â Peptostreptococcus</span> spp.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8f84f34f-84d5-02e4-ef20-1eb4c4ad242c"></a><a name="section-3.2.4"></a><p></p>
<h3>Anaerobic gram-negative microorganisms</h3>
<p class="First"><span class="Italics">Â Bacteroides distasonis</span></p>
<p><span class="Italics">Â Bacteroides fragilis</span></p>
<p><span class="Italics">Â Bacteroides ovatus</span></p>
<p><span class="Italics">Â Bacteroides thetaiotaomicron</span></p>
<p><span class="Italics">Â Bacteroides</span> spp.</p>
<p>The following <span class="Italics">in vitro</span> data are available, <span class="Underline"><span class="Bold">but their clinical significance is unknown.</span></span></p>
<p>Cefoxitin exhibits <span class="Italics">in vitro</span> <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MIC's) of 8 mcg/mL or less for aerobic microorganisms and 16 mcg/mL or less for anaerobic microorganisms against most (â‰¥ 90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms; however, the safety and effectiveness of cefoxitin in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled clinical trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_39f97277-35ff-d043-7eac-abd44274bea4"></a><a name="section-3.2.5"></a><p></p>
<h3>Aerobic gram-negative microorganisms</h3>
<p class="First"><span class="Italics">Â Eikenella corrodens</span> [non-ÃŸ-lactamase producers]</p>
<p><span class="Italics">Â Klebsiella oxytoca</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c7b522bc-baba-bc25-c578-8e21ef36700d"></a><a name="section-3.2.6"></a><p></p>
<h3>Anaerobic gram-positive microorganisms</h3>
<p class="First"><span class="Italics">Â Clostridium perfringens</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7e6f277c-3396-213e-537a-abfe4f2d5937"></a><a name="section-3.2.7"></a><p></p>
<h3>Anaerobic gram-negative microorganisms</h3>
<p class="First"><span class="Italics">Prevotella bivia</span> (formerly<span class="Italics">Bacteroides bivius</span>)</p>
<p>Cefoxitin is inactive <span class="Italics">in vitro</span> against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Pseudomonas aeruginosa</span> and enterococci and many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Enterobacter cloacae.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cd359c87-16e0-d4e9-6347-11751d870c4e"></a><a name="section-3.2.8"></a><p></p>
<h3>Susceptibility Tests</h3>
<p class="First"><span class="Underline">Dilution Techniques:</span></p>
<p>Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICâ€™s). These MICâ€™s provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICâ€™s should be determined using a standardized procedure. Standardized procedures are based on a dilution method(<a href="#LINK_00f87138-f22b-a9be-fe3e-032f260fed1b">1</a>) (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of cefoxitin powder. The MIC values should be interpreted according to the following criteria:</p>
<table border="single" frame="void">
<caption><span>For testing aerobic microorganisms<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>,<a name="footnote-reference-3" href="#footnote-3" class="Sup">â€ </a>, <a name="footnote-reference-4" href="#footnote-4" class="Sup">â€¡</a> other than Neisseria gonorrhoeae</span></caption>
<col>
<col>
<thead><tr class="First Last">
<td valign="top">Â Â <span class="Bold">MIC (mcg/mL)</span>
</td>
<td valign="top">Â Â <span class="Bold">Interpretation</span>
</td>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Staphylococci exhibiting resistance to methicillin/oxacillin should be reported as also resistant to cefoxitin despite apparent <span class="Italics">in vitro</span> susceptibility.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€ </a></dt>
<dd>For testing <span class="Italics">Haemophilus influenzae</span> these interpretative criteria applicable only to tests performed by broth microdilution method using Haemophilus Test Medium (HTM) <a href="#LINK_00f87138-f22b-a9be-fe3e-032f260fed1b">(1)</a>.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">â€¡</a></dt>
<dd>For testing streptococci these interpretative criteria applicable only to tests performed by broth microdilution method using cation-adjusted Mueller-Hinton broth with 2 to 5% lysed horse blood <a href="#LINK_00f87138-f22b-a9be-fe3e-032f260fed1b">(1)</a>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td valign="top">Â Â â‰¤ 8</td>
<td valign="top">Â Â Susceptible (S)</td>
</tr>
<tr>
<td valign="top">Â Â 16</td>
<td valign="top">Â Â Intermediate (I)</td>
</tr>
<tr class="Last">
<td valign="top">Â Â â‰¥ 32</td>
<td valign="top">Â Â Resistant (R)</td>
</tr>
</tbody>
</table>
<table border="single" frame="void">
<caption><span>For testing Neisseria gonorrhoeae<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>:</span></caption>
<col>
<col>
<thead><tr class="First Last">
<td valign="top">Â Â <span class="Bold">MIC (mcg/mL)</span>
</td>
<td valign="top">Â Â <span class="Bold">Interpretation</span>
</td>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Interpretative criteria applicable only to tests performed by agar dilution method using GC agar base with 1% defined growth supplement and incubated in 5% CO<span class="Sub">2</span><a href="#LINK_00f87138-f22b-a9be-fe3e-032f260fed1b">(1)</a>. A report of â€œSusceptibleâ€? indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of â€œIntermediateâ€? indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of â€œResistantâ€? indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td valign="top">Â Â â‰¤ 2</td>
<td valign="top">Â Â Susceptible (S)</td>
</tr>
<tr>
<td valign="top">Â Â 4</td>
<td valign="top">Â Â Intermediate (I)</td>
</tr>
<tr class="Last">
<td valign="top">Â Â â‰¥ 8</td>
<td valign="top">Â Â Resistant (R)</td>
</tr>
</tbody>
</table>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard cefoxitin powder should provide the following MIC values:</p>
<table border="single" frame="void">
<col>
<col>
<col>
<thead><tr class="First Last">
<td valign="top">Â <span class="Bold">Â Microorganism</span>
</td>
<td valign="top">Â Â </td>
<td valign="top">Â Â <span class="Bold">MIC (mcg/mL)</span>
</td>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Interpretative criteria applicable only to tests performed by agar dilution method using GC agar base with 1% defined growth supplement and incubated in 5% CO<span class="Sub">2</span><a href="#LINK_00f87138-f22b-a9be-fe3e-032f260fed1b">(1)</a>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td valign="top">Â Â <span class="Italics">Escherichia coli</span>
</td>
<td valign="top">Â Â ATCC 25922</td>
<td valign="top">Â Â 1-4</td>
</tr>
<tr>
<td valign="top">Â Â <span class="Italics">Neisseria gonorrhoeae</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a>
</td>
<td valign="top">Â Â ATCC 49226</td>
<td valign="top">Â Â 0.5-2</td>
</tr>
<tr class="Last">
<td valign="top">Â Â <span class="Italics">Staphylococcus aureus</span>
</td>
<td valign="top">Â Â ATCC 29213</td>
<td valign="top">Â Â 1-4</td>
</tr>
</tbody>
</table>
<p><span class="Underline">Diffusion Techniques:</span></p>
<p>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure (2) requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 30-mcg cefoxitin to test the susceptibility of microorganisms to cefoxitin.</p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30-mcg cefoxitin disk should be interpreted according to the following criteria:</p>
<table border="single" frame="void">
<caption><span>For testing aerobic microorganisms <a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a><a name="footnote-reference-8" href="#footnote-8" class="Sup">â€ </a><a name="footnote-reference-9" href="#footnote-9" class="Sup">â€¡</a> other than Neisseria gonorrhoeae:</span></caption>
<col>
<col>
<thead><tr class="First Last">
<td valign="top">Â Â <span class="Bold">Zone Diameter (mm)</span>
</td>
<td valign="top">Â Â <span class="Bold">Interpretation</span>
</td>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Staphylococci exhibiting resistance to methicillin/oxacillin should be reported as also resistant to cefoxitin despite apparent <span class="Italics">in vitro</span> susceptibility.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">â€ </a></dt>
<dd>For testing <span class="Italics">Haemophilus influenzae</span> these interpretative criteria applicable only to tests performed by disk diffusion method using Haemophilus Test Medium (HTM) <a href="#LINK_00f87138-f22b-a9be-fe3e-032f260fed1b">(1)</a>.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">â€¡</a></dt>
<dd>For testing streptococci these interpretative criteria applicable only to tests performed by disk diffusion method using Mueller-Hinton agar with 5% defibrinated sheep blood and incubated in 5% CO<span class="Sub">2</span><a href="#LINK_00f87138-f22b-a9be-fe3e-032f260fed1b">(2)</a>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td valign="top">Â Â â‰¥ 18</td>
<td valign="top">Â Â Susceptible (S)</td>
</tr>
<tr>
<td valign="top">Â Â 15-17</td>
<td valign="top">Â Â Intermediate (I)</td>
</tr>
<tr class="Last">
<td valign="top">Â Â â‰¤ 14</td>
<td valign="top">Â Â Resistant (R)</td>
</tr>
</tbody>
</table>
<table border="single" frame="void">
<caption><span>For testing Neisseria gonorrhoeae<a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a>:</span></caption>
<col>
<col>
<thead><tr class="First Last">
<td valign="top">Â Â <span class="Bold">Zone Diameter (mm)</span>
</td>
<td valign="top">Â Â <span class="Bold">Interpretation</span>
</td>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>Interpretative criteria applicable only to tests performed by disk diffusion method using GC agar base with 1% defined growth supplement and incubated in 5% CO<span class="Sub">2</span><a href="#LINK_00f87138-f22b-a9be-fe3e-032f260fed1b">(2)</a>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td valign="top">Â Â â‰¥ 28</td>
<td valign="top">Â Â Susceptible (S)</td>
</tr>
<tr>
<td valign="top">Â Â 24-27</td>
<td valign="top">Â Â Intermediate (I)</td>
</tr>
<tr class="Last">
<td valign="top">Â Â â‰¤ 23</td>
<td valign="top">Â Â Resistant (R)</td>
</tr>
</tbody>
</table>
<p>Interpretation should be as stated above for results using dilution techniques.</p>
<p>Interpretation involves correlation of the diameter obtained in the disk test with the MIC for cefoxitin.</p>
<p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 30-mcg cefoxitin disk should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<table border="single" frame="void">
<col>
<col>
<col>
<thead><tr class="First Last">
<td valign="top">Â <span class="Bold">Â Microorganism</span>
</td>
<td valign="top">Â Â </td>
<td align="center" valign="top">Â Â <span class="Bold">Zone Diameter (mm)</span>
</td>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>Interpretative criteria applicable only to tests performed by disk diffusion method using GC agar base with 1% defined growth supplement and incubated in 5% CO<span class="Sub">2</span><a href="#LINK_00f87138-f22b-a9be-fe3e-032f260fed1b">(2)</a>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td valign="top">Â Â <span class="Italics">Escherichia coli</span>
</td>
<td valign="top">Â Â ATCC 25922</td>
<td align="center" valign="top">Â Â 23-29</td>
</tr>
<tr>
<td valign="top">Â Â <span class="Italics">Neisseria gonorrhoeae</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a>
</td>
<td valign="top">Â Â ATCC 49226</td>
<td align="center" valign="top">Â Â 33-41</td>
</tr>
<tr class="Last">
<td valign="top">Â Â <span class="Italics">Staphylococcus aureus</span>
</td>
<td valign="top">Â Â ATCC 25923</td>
<td align="center" valign="top">Â Â 23-29</td>
</tr>
</tbody>
</table>
<p><span class="Underline">Anaerobic Techniques:</span></p>
<p>For anaerobic bacteria, the susceptibility to cefoxitin as MICâ€™s can be determined by standardized test methods (<a href="#LINK_00f87138-f22b-a9be-fe3e-032f260fed1b">3</a>). The MIC values obtained should be interpreted according to the following criteria:</p>
<table border="single" frame="void">
<col>
<col>
<thead><tr class="First Last">
<td valign="top">Â Â <span class="Bold">MIC (mcg/mL)</span>
</td>
<td valign="top">Â Â <span class="Bold">Interpretation</span>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td valign="top">Â Â â‰¤ 16</td>
<td valign="top">Â Â Susceptible (S)</td>
</tr>
<tr>
<td valign="top">Â Â 32</td>
<td valign="top">Â Â Intermediate (I)</td>
</tr>
<tr class="Last">
<td valign="top">Â Â â‰¥ 64</td>
<td valign="top">Â Â Resistant (R)</td>
</tr>
</tbody>
</table>
<p>Interpretation is identical to that stated above for results using dilution techniques.</p>
<p>As with other susceptibility techniques, the use of laboratory control microorganisms is required to control the technical aspects of the laboratory standardized procedures. Standard cefoxitin powder should provide the following MIC values:</p>
<table border="single" frame="void">
<caption><span>Using either an Agar Dilution Method<a name="footnote-reference-12" href="#footnote-12" class="Sup">*</a> or Using a Broth<a name="footnote-reference-13" href="#footnote-13" class="Sup">â€ </a> Microdilution Method:</span></caption>
<col>
<col>
<col>
<thead><tr class="First Last">
<td valign="top">Â <span class="Bold">Â Microorganism</span>
</td>
<td valign="top">Â Â </td>
<td valign="top">Â <span class="Bold">Â MIC (mcg/mL)</span>
</td>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-12" href="#footnote-reference-12">*</a></dt>
<dd>Range applicable only to tests performed using either Brucella blood or Wilkins-Chalgren agar.</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">â€ </a></dt>
<dd>Range applicable only to tests performed in the broth formulation of Wilkins-Chalgren agar <a href="#LINK_00f87138-f22b-a9be-fe3e-032f260fed1b">(3)</a>
</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td valign="top">Â Â <span class="Italics">Bacteroides fragilis</span>
</td>
<td valign="top">Â Â ATCC 25285</td>
<td valign="top">Â Â 4-16</td>
</tr>
<tr class="Last">
<td valign="top">Â Â <span class="Italics">Bacteroides thetaiotaomicron</span>
</td>
<td valign="top">Â Â ATCC 29741</td>
<td valign="top">Â Â 8-32</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_e700b01e-ccd1-353f-31af-e7682c0755d2"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a4ca08a0-19f5-e31c-d268-a5e0386fc94f"></a><a name="section-4.1"></a><p></p>
<h2>Treatment</h2>
<p class="First">Cefoxitin for injection is indicated for the treatment of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the diseases listed below.</p>
<ul class="Disk">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower respiratory tract infections</span>,</span> including <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> and <span class="product-label-link" type="condition" conceptid="257010" conceptname="Abscess of lung">lung abscess</span>, caused by <span class="Italics">Streptococcus pneumoniae</span>, other streptococci (excluding enterococci, e.g., <span class="Italics">Enterococcus faecalis</span> [formerly <span class="Italics">Streptococcus faecalis</span>]), <span class="Italics">Staphylococcus aureus</span> (including penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Escherichia coli, Klebsiella</span> species, <span class="Italics">Haemophilus influenzae,</span> and <span class="Italics">Bacteroides</span> species.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span> </span>caused by <span class="Italics">Escherichia coli, Klebsiella </span>species, <span class="Italics">Proteus mirabilis, Morganella morganii, Proteus vulgaris</span> and <span class="Italics">Providencia</span> species (including <span class="Italics">P.Â rettgeri</span>).</li>
<li>
<span class="Bold">Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span>,</span> including <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> and intra-<span class="product-label-link" type="condition" conceptid="4326255" conceptname="Abdominal abscess">abdominal abscess</span>, caused by <span class="Italics">Escherichia coli, Klebsiella</span> species, <span class="Italics">Bacteroides</span> species including <span class="Italics">Bacteroides fragilis</span>, and <span class="Italics">Clostridium</span> species.</li>
<li>
<span class="Bold">Gynecological <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>,</span> including <span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">endometritis</span>, pelvic <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, and <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> caused by <span class="Italics">Escherichia coli</span>, <span class="Italics">Neisseria gonorrhoeae</span> (including penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Bacteroides</span> species including <span class="Italics">B.Â fragilis,</span><span class="Italics">Clostridium</span> species, <span class="Italics">Peptococcus</span>Â <span class="Italics">niger</span>, <span class="Italics">Peptostreptococcus</span> species, and <span class="Italics">Streptococcus agalactiae</span>. Cefoxitin for injection, like cephalosporins, has no activity against <span class="Italics">Chlamydia trachomatis</span>. Therefore, when Cefoxitin for injection is used in the treatment of patients with <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> and <span class="Italics">C.Â trachomatis</span> is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Septicemia</span></span> caused by <span class="Italics">Streptococcus pneumoniae</span>, <span class="Italics">Staphylococcus aureus</span> (including penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Escherichia coli, Klebsiella</span> species, and <span class="Italics">Bacteroides</span> species including <span class="Italics">B.Â fragilis.</span>
</li>
<li>
<span class="Bold">Bone and <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">joint infections</span></span> caused by <span class="Italics">Staphylococcus aureus</span> (including penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>).</li>
<li>
<span class="Bold">Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></span> caused by <span class="Italics">Staphylococcus aureus</span> (including penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Staphylococcus epidermidis, Streptococcus pyogenes </span>and other streptococci (excluding enterococci e.g., <span class="Italics">Enterococcus faecalis</span> [formerly <span class="Italics">Streptococcus faecalis</span>]), <span class="Italics">Escherichia coli, Proteus mirabilis, Klebsiella</span> species, <span class="Italics">Bacteroides</span> species including <span class="Italics">B.Â fragilis</span>, <span class="Italics">Clostridium</span> species, <span class="Italics">Peptococcus</span>Â <span class="Italics">niger</span>, and <span class="Italics">Peptostreptococcus</span> species.</li>
</ul>
<p>Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to cefoxitin. Therapy may be started while awaiting the results of these studies.</p>
<p>In randomized comparative studies, cefoxitin and cephalothin were comparably safe and effective in the management of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases.</p>
<p>Many <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to cefoxitin. Similarly, many <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillinÂ G) respond to treatment with cefoxitin. Many <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with cefoxitin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8398b6d6-67a5-caf1-0c73-a1875267ebbf"></a><a name="section-4.2"></a><p></p>
<h2>Prevention</h2>
<p class="First">Cefoxitin for injection is indicated for the prophylaxis of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in patients undergoing uncontaminated gastrointestinal surgery, vaginal hysterectomy, abdominal hysterectomy, or cesarean section.</p>
<p>If there are signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, specimens for culture should be obtained for identification of the causative organism so that appropriate treatment may be instituted.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefoxitin for injection and other antibacterial drugs, cefoxitin for injection should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_a9fb849f-ad0d-4379-a4f6-bc125849ae10"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Cefoxitin for injection is contraindicated in patients who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to cefoxitin and the cephalosporin group of antibiotics.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_5c64b0cb-4afd-301d-d189-b52fda9afcc8"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">BEFORE THERAPY WITH CEFOXITIN FOR INJECTION IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO CEFOXITIN, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. THIS PRODUCT SHOULD BE GIVEN WITH CAUTION TO PENICILLIN-SENSITIVE PATIENTS. ANTIBIOTICS SHOULD BE ADMINISTERED WITH CAUTION TO ANY PATIENT WHO HAS DEMONSTRATED SOME FORM OF <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGY</span>, PARTICULARLY TO DRUGS. IF AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> TO CEFOXITIN FOR INJECTION OCCURS, DISCONTINUE THE DRUG. SERIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> MAY REQUIRE EPINEPHRINE AND OTHER EMERGENCY MEASURES.</p>
<p><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with the use of nearly all antibacterial agents, including Cefoxitin for injection, and it may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile </span>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile, </span>and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_e1ee0cfe-2f34-40d1-8898-e49961a231ac"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_2e35d8e6-18f0-0d02-6ce1-e188a3b96d7a"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">The total daily dose should be reduced when Cefoxitin for injection is administered to patients with transient or persistent reduction of urinary output due to <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (see <a href="#LINK_31c5acb5-bbac-4350-b4e6-a7d66f159381">DOSAGE AND ADMINISTRATION</a>), because high and prolonged serum antibiotic concentrations can occur in such individuals from usual doses.</p>
<p>Antibiotics (including cephalosporins) should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p>As with other antibiotics, prolonged use of cefoxitin for injection may result in overgrowth of nonsusceptible organisms. Repeated evaluation of the patient's condition is essential. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs during therapy, appropriate measures should be taken.</p>
<p>Prescribing cefoxitin for injection in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_0db6fcb6-f2a1-4e1f-963f-ade3054cf26f"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including cefoxitin for injection should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When cefoxitin for injection is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Physicians are advised to counsel patients that skipping doses or not completing the full course of therapy may: decrease the effectiveness of the immediate treatment and,Â increase the likelihood that bacteria will develop resistance and will not be treatable by cefoxitin for injection or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics, which usually ends when the antibiotic is discontinued. Sometimes after starting the treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="LINK_c039b2b0-0867-abe4-0119-3b42d2a8ed17"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">As with any potent antibacterial agent, periodic assessment of organ system functions, including renal, hepatic, and hematopoietic, is advisable during prolonged therapy.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_e75632ec-a260-6ecf-bf8d-182f830b1e00"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Increased <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="LINK_dddf0a72-9db4-1cfd-069e-f64e1144ebce"></a><a name="section-7.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">As with cephalothin, high concentrations of cefoxitin (&gt;100 micrograms/mL) may interfere with measurement of serum and urine creatinine levels by the JaffÃ© reaction, and produce false increases of modest degree in the levels of creatinine reported. Serum samples from patients treated with cefoxitin should not be analyzed for creatinine if withdrawn within 2 hours of drug administration.</p>
<p>High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported.</p>
<p>A false-positive reaction for glucose in the urine may occur. This has been observed with CLINITEST<a name="footnote-reference-14" href="#footnote-14" class="Sup">2</a> reagent tablets.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">2</a></dt>
<dd><p class="First">Registered trademark of Ames Company, Division of Miles Laboratories, Inc.</p></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_4b637231-a8b8-c102-2876-d0c937661a27"></a><a name="section-7.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis,Â ImpairmentÂ ofÂ Fertility</h2>
<p class="First">Long-term studies in animals have not been performed with cefoxitin to evaluate carcinogenic or mutagenic potential. Studies in rats treated intravenously with 400Â mg/kg of cefoxitin (approximately three times the maximum recommended human dose) revealed no effects on fertility or mating ability.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_329c4ea6-3a45-cb54-9947-9d436d888ca6"></a><a name="section-7.7"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy CategoryÂ B.</span> Reproduction studies performed in rats and mice at parenteral doses of approximately one to seven and one-half times the maximum recommended human dose did not reveal teratogenic or fetal toxic effects, although a slight decrease in fetal weight was observed.</p>
<p>There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
<p>In the rabbit, cefoxitin was associated with a high incidence of abortion and maternal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. This was not considered to be a teratogenic effect but an expected consequence of the rabbit's unusual sensitivity to antibiotic-induced changes in the population of the microflora of the intestine.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_408272b9-23d1-1fec-4b27-04de3f221a5a"></a><a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Cefoxitin is excreted in human milk in low concentrations. Caution should be exercised when cefoxitin is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_1c5a6402-2ca8-bdc6-2ffc-dc0c00770fd0"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and efficacy in pediatric patients from birth to three months of age have not yet been established. In pediatric patients three months of age and older, higher doses of cefoxitin have been associated with an increased incidence of <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and elevated <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_2e44a25f-81cf-0f10-8a99-07426f3ef208"></a><a name="section-7.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Of the 1,775 subjects who received cefoxitin in clinical studies, 424 (24%) were 65 and over, while 124 (7%) were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out (see <a href="#LINK_4bcc12d3-53d6-de4e-d971-7752e9e5ed39">CLINICAL PHARMACOLOGY</a>). This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see <a href="#LINK_31c5acb5-bbac-4350-b4e6-a7d66f159381">DOSAGE AND ADMINISTRATION</a> and <a href="#LINK_e1ee0cfe-2f34-40d1-8898-e49961a231ac">PRECAUTIONS</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_2a962f38-80d3-4162-9687-4f40a8117964"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Cefoxitin for injection is generally well tolerated. The most common adverse reactions have been local reactions following intravenous injection. Other adverse reactions have been encountered infrequently.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_727d1a1d-f262-7e43-31a3-a8dc0577f958"></a><a name="section-8.1"></a><p></p>
<h2>Local Reactions</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> has occurred with intravenous administration. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6df2cc0d-cecb-34f8-e6f3-48a62607523b"></a><a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (including <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>), <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> have been noted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2edc6bc2-d312-be1c-cf2c-f0b554248edd"></a><a name="section-8.3"></a><p></p>
<h2>Cardiovascular</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3b903be3-2ddf-82fe-a5ca-d5061990465a"></a><a name="section-8.4"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, including documented <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> which can appear during or after antibiotic treatment. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> have been reported rarely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_de92ad0e-8dab-c394-0635-e486da5f5b35"></a><a name="section-8.5"></a><p></p>
<h2>Neuromuscular</h2>
<p class="First">Possible exacerbation of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_dd0bf99c-d64f-69c8-7088-1fc4655265da"></a><a name="section-8.6"></a><p></p>
<h2>Blood</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> including <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, including <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>. A positive direct Coombs test may develop in some individuals, especially those with <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1f15683c-68f9-8197-caf4-413da4a0860f"></a><a name="section-8.7"></a><p></p>
<h2>Liver Function</h2>
<p class="First">Transient elevations in <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, SGPT, serum LDH, and serum alkaline phosphatase; and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8e1c3ff7-ac09-b98e-b0f3-ac5f36f73ec9"></a><a name="section-8.8"></a><p></p>
<h2>Renal Function</h2>
<p class="First">Elevations in serum creatinine and/or blood urea nitrogen levels have been observed. As with the cephalosporins, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> has been reported rarely. The role of cefoxitin in changes in renal function tests is difficult to assess, since factors predisposing to prerenal <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> or to <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> usually have been present.</p>
<p>In addition to the adverse reactions listed above which have been observed in patients treated with cefoxitin, the following adverse reactions and altered laboratory test results have been reported for cephalosporin class antibiotics:</p>
<p><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like reactions, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, renal dysfunction, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>, false-positive test for urinary glucose, hepatic dysfunction including <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, elevated bilirubin, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, prolonged <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> including <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>.</p>
<p>Several cephalosporins have been implicated in triggering <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> when the dosage was not reduced. (See <a href="#LINK_31c5acb5-bbac-4350-b4e6-a7d66f159381">DOSAGE AND ADMINISTRATION</a>.) If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.</p>
<p>To report SUSPECTED ADVERSE EVENTS, contact FDA at 1-800-FDA-1088 or www.fda.gov.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_e3f4d671-04b3-0eba-2162-433b73fab58b"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The acute intravenous LD<span class="Sub">50</span> in the adult female mouse and rabbit was about 8Â g/kg and greater than 1Â g/kg, respectively. The acute intraperitoneal LD<span class="Sub">50</span> in the adult rat was greater than 10Â g/kg.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_31c5acb5-bbac-4350-b4e6-a7d66f159381"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">The intent of this Pharmacy Bulk Package is for the preparation of solutions for intravenous infusion only.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2a03bbc6-c8ff-7523-f937-ea649fa0832e"></a><a name="section-10.1"></a><p></p>
<h2>TREATMENT</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d4531383-4350-3e63-3fa1-dedadc731883"></a><a name="section-10.1.1"></a><p></p>
<h3>Adults</h3>
<p class="First">The usual adult dosage range is 1Â gram to 2Â grams every six to eight hours. Dosage should be determined by susceptibility of the causative organisms, severity of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and the condition of the patient (see TableÂ 1 for dosage guidelines).</p>
<p>If <span class="Italics">C.Â trachomatis</span> is a suspected pathogen, appropriate anti-chlamydial coverage should be added, because cefoxitin sodium has no activity against this organism.</p>
<p>Cefoxitin for injection may be used in patients with reduced renal function with the following dosage adjustments:</p>
<p><span class="Bold">In adults with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>,</span> an initial loading dose of 1Â gram to 2Â grams may be given. After a loading dose, the recommendations for <span class="Italics">maintenance dosage</span> (TableÂ 2) may be used as a guide.</p>
<p><span class="Bold">When only the serum creatinine level is available,</span> the following formula (based on sex, weight, and age of the patient) may be used to convert this value into creatinine clearance. The serum creatinine should represent a steady state of renal function.</p>
<p>Males Â Â Â Â Â Â Â Â Â Â Â Â =Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="Underline">Weight (kg) x (140-age)</span><br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 72 x serum creatinine (mg/100 mL)</p>
<p>Females Â Â Â Â Â Â Â Â =Â Â Â Â Â Â Â Â Â Â Â Â Â 0.85 x male value</p>
<p><span class="Bold">In patients undergoing hemodialysis,</span> the loading dose of 1 to 2Â grams should be given after each hemodialysis, and the maintenance dose should be given as indicated in TableÂ 2.</p>
<p>Antibiotic therapy for groupÂ A beta-hemolytic <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span> should be maintained for at least 10Â days to guard against the risk of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> or <span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">glomerulonephritis</span>. In staphylococcal and other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> involving a collection of pus, surgical drainage should be carried out where indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_489f4d1c-7139-3b04-700f-302d2d548201"></a><a name="section-10.1.2"></a><p></p>
<h3>Pediatric Patients</h3>
<p class="First">The recommended dosage in pediatric patients three months of age and older is 80 to 160Â mg/kg of body weight per day divided into four to six equal doses. The higher dosages should be used for more severe or serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. The total daily dosage should not exceed 12Â grams.</p>
<p>At this time no recommendation is made for pediatric patients from birth to three months of age (see <a href="#LINK_e1ee0cfe-2f34-40d1-8898-e49961a231ac">PRECAUTIONS</a>).</p>
<p>In pediatric patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, the dosage and frequency of dosage should be modified consistent with the recommendations for adults (see TableÂ 2).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5769775b-e056-b63e-bc12-e8f48c061c82"></a><a name="section-10.2"></a><p></p>
<h2>PREVENTION</h2>
<p class="First">Effective <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use depends on the time of administration. Cefoxitin for injection usually should be given one-half to one hour before the operation, which is sufficient time to achieve effective levels in the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> during the procedure. <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> administration should usually be stopped within 24Â hours since continuing administration of any antibiotic increases the possibility of adverse reactions but, in the majority of surgical procedures, does not reduce the incidence of subsequent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>For <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use in uncontaminated gastrointestinal surgery, vaginal hysterectomy, or abdominal hysterectomy, the following doses are recommended:</p>
<p><span class="Italics">Adults:</span></p>
<p>2 grams administered intravenously just prior to surgery (approximately one-half to one hour before the initial incision) followed by 2Â grams every 6Â hours after the first dose for no more than 24Â hours.</p>
<p><span class="Italics">Pediatric Patients</span> (3 months and older):</p>
<p>30 to 40Â mg/kg doses may be given at the times designated above.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d2e0f21d-5855-a335-b631-713e59cb51a4"></a><a name="section-10.2.1"></a><p></p>
<h3>Cesarean section patients:</h3>
<p class="First">For patients undergoing cesarean section, either a single 2Â gram dose administered intravenously as soon as the umbilical cord is clamped OR a 3-dose regimen consisting of 2Â grams given intravenously as soon as the umbilical cord is clamped followed by 2Â grams 4 and 8Â hours after the initial dose is recommended. (See <a href="#LINK_346afcc8-e51e-b273-54fb-895a8bf284c2">CLINICAL STUDIES</a>.)</p>
<table border="single" frame="void">
<caption><span>Table 1: Guidelines for DosageÂ ofÂ Cefoxitin for Injection</span></caption>
<col>
<col>
<col>
<thead><tr class="First Last">
<td align="center" valign="top">Â Â Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td align="center" valign="top">Â Â Daily Dosage</td>
<td align="center" valign="top">Â Â Frequency and Route</td>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>Including patients in whom <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> is absent or unlikely.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td valign="top">Â Â Uncomplicated forms<a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a> of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> such as <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, cutaneous <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></td>
<td align="center" valign="top">Â Â 3-4 grams</td>
<td align="center" valign="top">Â Â 1 gram every 6-8 hours IV</td>
</tr>
<tr>
<td valign="top">Â Â Moderately severe or severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></td>
<td align="center" valign="top">Â Â 6-8 grams</td>
<td align="center" valign="top">Â Â 1 gram every 4Â hours<br><span class="Italics">or</span><br>2 grams every 6-8Â hoursÂ IV</td>
</tr>
<tr class="Last">
<td valign="top">Â Â <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> commonly needing antibiotics in higher dosage (e.g., <span class="product-label-link" type="condition" conceptid="433696" conceptname="Gas gangrene">gas gangrene</span>)</td>
<td align="center" valign="top">Â Â 12 grams</td>
<td align="center" valign="top">Â Â 2 grams every 4Â hours<br><span class="Italics">or</span><br>3Â grams every 6Â hoursÂ IV</td>
</tr>
</tbody>
</table>
<table border="single" frame="void">
<caption><span>Table 2: Maintenance Dosage of Cefoxitin for Injection in Adults withÂ ReducedÂ RenalÂ Function</span></caption>
<col>
<col>
<col>
<col>
<thead><tr class="First Last">
<td valign="top">Â Â Renal Function<br>
</td>
<td align="center" valign="top">Â Â Creatinine Clearance<br>(mL/min)</td>
<td align="center" valign="top">Â Â Dose<br>(grams)</td>
<td align="center" valign="top">Â Â Frequency<br>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td valign="top">Â Â Mild impairment</td>
<td align="center" valign="top">Â Â 50-30</td>
<td align="center" valign="top">Â Â 1-2</td>
<td align="center" valign="top">Â Â every 8-12 hours</td>
</tr>
<tr>
<td valign="top">Â Â Moderate impairment</td>
<td align="center" valign="top">Â Â 29-10</td>
<td align="center" valign="top">Â Â 1-2</td>
<td align="center" valign="top">Â Â every 12-24 hours</td>
</tr>
<tr>
<td valign="top">Â Â Severe impairment</td>
<td align="center" valign="top">Â Â 9-5</td>
<td align="center" valign="top">Â Â 0.5-1</td>
<td align="center" valign="top">Â Â every 12-24 hours</td>
</tr>
<tr class="Last">
<td valign="top">Â Â Essentially no function</td>
<td align="center" valign="top">Â Â &lt;5</td>
<td align="center" valign="top">Â Â 0.5-1</td>
<td align="center" valign="top">Â Â every 24-48 hours</td>
</tr>
</tbody>
</table>
<table border="single" frame="void">
<caption><span>Table 3: Preparation of Solution for Intravenous Administration</span></caption>
<col>
<col>
<col>
<col>
<thead><tr class="First Last">
<td align="center" valign="top">Â Â Strength</td>
<td align="center" valign="top">Â Â Amount of Diluent to be Added (mL)<a name="footnote-reference-16" href="#footnote-16" class="Sup">*</a>
</td>
<td align="center" valign="top">Â Â Approximate Withdrawable Volume (mL)</td>
<td align="center" valign="top">Â Â Approximate Average Concentration (mg/mL)</td>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-16" href="#footnote-reference-16">*</a></dt>
<dd>Shake to dissolve and let stand until clear.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="center" valign="top">Â 10 grams Pharmacy Bulk Package</td>
<td align="center" valign="top">Â 43 or 93</td>
<td align="center" valign="top">Â 49 or 98.5</td>
<td align="center" valign="top">Â Â 200 or 100</td>
</tr>
<tr>
<td align="center" valign="top">Â Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â Â </td>
<td align="center" valign="top">Â Â </td>
</tr>
<tr>
<td align="center" valign="top">Â Â </td>
<td align="center" valign="top">Â Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td align="center" valign="top">Â Â </td>
<td align="center" valign="top">Â Â  </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr class="Last">
<td align="center" valign="top">Â Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_32c324b4-e51a-4b54-93de-d0be67ffdc9c"></a><a name="section-10.3"></a><p></p>
<h2>DIRECTIONS FOR PROPER USE OF PHARMACY BULK PACKAGE BOTTLE - NOT FOR DIRECT INFUSION</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_48c65153-5da7-45f6-646d-e4d731a71977"></a><a name="section-10.3.1"></a><p></p>
<h3>For Bulk Packages</h3>
<p class="First">The Pharmacy Bulk Package bottle is for use in a pharmacy admixture service under a laminar flow hood. Penetration into the Pharmacy Bulk Package bottle should be made only one time after reconstitution with a sterile transfer set or other sterile dispensing device, which allows measured distribution of the contents. Dispense the contents in aliquots using aseptic technique. The use of a syringe with a needle is not recommended as it may cause leakage.</p>
<p>AFTER INITIAL ENTRY USE ENTIRE CONTENTS OF THE PHARMACY BULK PACKAGE PROMPTLY. A maximum time of <span class="Bold">4 HOURS </span>from initial entry is permitted to complete fluid transfer operations. ANY UNUSED PORTION MUST BE DISCARDED WITHIN <span class="Bold">4 HOURS.</span> This time limit should begin with the introducing of solvent or diluent into the Pharmacy Bulk Package bottle. <span class="Bold">RECONSTITUTED BULK SOLUTION SHOULD NOT BE USED FOR DIRECT INFUSION.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d3c02657-d646-4940-aaf0-4335cfe84201"></a><a name="section-10.3.2"></a><p></p>
<h3>Preparation of Solution</h3>
<p class="First">The directions for preparing cefoxitin for injection Pharmacy Bulk Package are summarized in Table 3.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_fa0f9acd-54d1-40ee-afec-dae966265c12"></a><a name="section-10.3.2.1"></a><p></p>
<h4>For Intravenous Use</h4>
<p class="First">The 10 grams bulk packages should be constituted with 43 or 93 mL of Sterile Water for Injection, Bacteriostatic Water for Injection, 0.9 percent Sodium Chloride Injection, or 5 percent Dextrose Injection.</p>
<p><span class="Bold">RECONSTITUTED STOCK SOLUTION MUST BE TRANSFERRED AND FURTHER DILUTED FOR I.V. INFUSION.</span></p>
<p>These primary solutions may be further diluted in 50 to 1000 mL of the diluents listed under the <span class="Italics">Bulk Packages </span>portion of the <a href="#LINK_6e5eba36-c8f7-40e4-9287-615ad424075b">COMPATIBILITY AND STABILITY</a>Â section.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9a0b02d4-9f61-1d38-80f9-411088e94c65"></a><a name="section-10.4"></a><p></p>
<h2>ADMINISTRATION</h2>
<p class="First">Cefoxitin for injection may be administered intravenously after constitution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. <span class="Bold">The intent of this pharmacy bulk package is for the preparation of solutions for intravenous infusion only.Â </span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8108b0f5-9135-52ba-4ef3-fc0473aca161"></a><a name="section-10.4.1"></a><p></p>
<h3>Intravenous Administration</h3>
<p class="First">The intravenous route is preferable for patients with <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>, bacterial <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>, or other severe or life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, or for patients who may be poor risks because of lowered resistance resulting from such debilitating conditions as <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or malignancy, particularly if <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> is present or impending.</p>
<p><span class="Italics">For intermittent intravenous administration.Â </span>Using an infusion system, aÂ solution containing 1Â gram or 2Â gramsÂ may be given over a longer period of time through the tubing system by which the patient may be receiving other intravenous solutions. However, during infusionsÂ of the solution containing cefoxitin for injection, it is advisable to temporarily discontinue administration of any other solutions at the same site.</p>
<p><span class="Italics">For the administration of higher doses by continuous intravenous infusion,</span> a solution of cefoxitin for injection may be added to an intravenous bottle containing 5Â percent Dextrose Injection, 0.9Â percent Sodium Chloride Injection, or 5Â percent Dextrose and 0.9Â percent Sodium Chloride Injection. BUTTERFLY<span class="Sup">Â®</span><a name="footnote-reference-17" href="#footnote-17" class="Sup">3</a> or scalp vein-type needles are preferred for this type of infusion.</p>
<p>Solutions of cefoxitin for injection, like those of most beta-lactam antibiotics, should not be added to aminoglycoside solutions (e.g., gentamicin sulfate, tobramycin sulfate, amikacin sulfate) because of potential interaction. However, cefoxitin for injection and aminoglycosides may be administered separately to the same patient.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-17" href="#footnote-reference-17">3</a></dt>
<dd>Registered trademark of Abbott Laboratories, Inc.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6e5eba36-c8f7-40e4-9287-615ad424075b"></a><a name="section-10.5"></a><p></p>
<h2>COMPATIBILITY AND STABILITY</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3f24d2d8-8af8-4f8e-9469-8a861ea56071"></a><a name="section-10.5.1"></a><p></p>
<h3>Pharmacy Bulk Packages</h3>
<p class="First">Cefoxitin for injection supplied in pharmacyÂ bulk package bottlesÂ and constituted to 1Â gram/10Â mL with Sterile Water for Injection, Bacteriostatic Water for Injection, (see <a href="#LINK_32c324b4-e51a-4b54-93de-d0be67ffdc9c">PREPARATION OF SOLUTION</a>), 0.9Â percent Sodium Chloride Injection, or 5Â percent Dextrose Injection, should be DISCARDED <span class="Bold">4 HOURS </span>AFTER INITIAL ENTRY, FURTHER DILUTION IS REQUIRED BEFORE USE. <span class="Bold">RECONSTITUTED BULK SOLUTION SHOULD NOT BE USED FOR DIRECT INFUSION.</span></p>
<p>These primary solutions may be further diluted in 50 to 1000Â mL of the following diluents and maintain potency for an additional 18Â hours at room temperature or an additional 48Â hours under refrigeration:</p>
<p>Â Â Â 0.9 percent Sodium Chloride Injection<br>Â Â Â 5 percent or 10 percent Dextrose Injection<br>Â Â Â 5 percent Dextrose and 0.9 percent Sodium Chloride Injection<br>Â Â Â 5 percent Dextrose Injection with 0.2Â percent or 0.45Â percent saline solution<br>Â Â Â Lactated Ringer's Injection<br>Â Â Â 5 percent Dextrose in Lactated Ringer's Injection<br>Â Â Â 5 percent Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> Injection<br>Â Â Â M/6 sodium lactate solution<br>Â Â Â Mannitol 5% and 10% </p>
<p>After the periods mentioned above, any unused solutions should be discarded.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_e6b55232-f66d-2fd1-f496-3a9b24cdff67"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Cefoxitin for Injection, USP is a dry white to off-white powder supplied in Pharmacy Bulk Package bottle. Each Pharmacy Bulk Package bottle contains cefoxitin sodium equivalent to 10 grams of cefoxitin.</p>
<p>Cefoxitin for Injection , USP 10 g, Pharmacy Bulk Package - (10 gram cefoxitin equivalent)<br>NDC 0143-9876-10 cartons of 10 pharmacy bulk packages</p>
<p><span class="Italics">Special storage instructions</span></p>
<p>Cefoxitin for injection in the dry state should be stored between 2-25ÂºC (36-77ÂºF). Avoid exposure to temperatures above 50ÂºC. The dry material as well as solutions tend to darken, depending on storage conditions; product potency, however, is not adversely affected.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_8462a26e-aac5-a220-9a54-84a415d9d159"></a><a name="section-11.1"></a><p></p>
<h2>Special storage instructions</h2>
<p class="First">MEFOXIN in the dry state should be stored between 2-25Â°C (36-77Â°F). Avoid exposure to temperatures above 50Â°C. The dry material as well as solutions tend to darken, depending on storage conditions; product potency, however, is not adversely affected.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_346afcc8-e51e-b273-54fb-895a8bf284c2"></a><a name="section-12"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">A prospective, randomized, double-blind, placebo-controlled clinical trial was conducted to determine the efficacy of short-term prophylaxis with cefoxitin in patients undergoing cesarean section who were at high risk for subsequent <span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">endometritis</span> because of ruptured membranes. Patients were randomized to receive either three doses of placebo (n=58), a single dose of cefoxitin (2Â g) followed by two doses of placebo (n=64), or a three-dose regimen of cefoxitin (each dose consisting of 2Â g) (n=60), given intravenously, usually beginning at the time of clamping of the umbilical cord, with the second and third doses given 4 and 8Â hours post-operatively. <span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">Endometritis</span> occurred in 16/58 (27.6%) patients given placebo, 5/63 (7.9%) patients given a single dose of cefoxitin, and 3/58 (5.2%) patients given three doses of cefoxitin. The differences between the two groups treated with cefoxitin and placebo with respect to <span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">endometritis</span> were statistically significant (p&lt;0.01) in favor of cefoxitin. The differences between the one-dose and three-dose regimens of cefoxitin were not statistically significant.</p>
<p>In clinical trials of patients with intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span> due to <span class="Italics">Bacteroides fragilis</span> group microorganisms, eradication rates at 1 to 2Â weeks post treatment for isolates were in the range of 70% to 80%. Eradication rates for individual species are listed below:</p>
<table border="single" frame="void">
<col width="33%">
<col width="33%">
<col width="34%">
<tbody class="Headless">
<tr class="First">
<td valign="top">Â Â <span class="Italics">Bacteroides distasonis</span>
</td>
<td valign="top">Â Â 7/10</td>
<td valign="top">Â Â (70%)</td>
</tr>
<tr>
<td valign="top">Â Â <span class="Italics">Bacteroides fragilis</span>
</td>
<td valign="top">Â Â 26/33</td>
<td valign="top">Â Â (79%)</td>
</tr>
<tr>
<td valign="top">Â Â <span class="Italics">Bacteroides ovatus</span>
</td>
<td valign="top">Â Â 10/13</td>
<td valign="top">Â Â (77%)</td>
</tr>
<tr class="Last">
<td valign="top">Â Â <span class="Italics">B. thetaiotaomicron</span>
</td>
<td valign="top">Â Â 13/18</td>
<td valign="top">Â Â (72%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_00f87138-f22b-a9be-fe3e-032f260fed1b"></a><a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<ul class="Disk">
<li>National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition. Approved Standard NCCLS Document M7-A4, Vol. 17, No. 2, NCCLS, Wayne, PA, January 1997.</li>
<li>National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests - Sixth Edition. Approved Standard NCCLS Document M2-A6, Vol. 17, No. 1, NCCLS, Wayne, PA, January 1997.</li>
<li>National Committee for Clinical Laboratory Standards. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria - Fourth Edition. Approved Standard NCCLS Document M11-A4, Vol. 17, No. 22, NCCLS, Villanova, PA, December 1997.</li>
</ul>
<p class="First"><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Manufactured by:<br></span>HIKMA FARMACEUTICA (PORTUGAL), S.A.<br>Estrada do Rio da Mo, nÂº 8, 8A e 8B - Fervenca,<br>2705 - 906 Terrugem SNT<br>PORTUGAL</p>
<p>for:</p>
<p>WEST-WARD PHARMACEUTICAL Corp.<br>465 Industrial Way West<br>EATONTOWN NJ 07724<br>USA</p>
<p>Iss. Mar. 2010</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_ee5cc474-153d-4c42-a368-dba544d351cd"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Cefoxitin for Injection, USP<br>Pharmacy Bulk Package<br>NDC 0143-9876-10</p>
<div class="Figure"><img alt="Cefoxitin for Injection, USP
Pharmacy Bulk Package" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6a4a2afa-4f00-41d4-bd6d-baa0a95f6929&amp;name=cefoxitin-injection-pbp-2.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFOXITINÂ 		
					</strong><br><span class="contentTableReg">cefoxitin injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0143-9876</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CEFOXITIN SODIUM</strong> (CEFOXITIN) </td>
<td class="formItem">CEFOXITIN SODIUM</td>
<td class="formItem">1Â g Â inÂ 10Â mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0143-9876-10</td>
<td class="formItem">10 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065239</td>
<td class="formItem">02/26/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>West-ward Pharmaceutical Corp
							(001230762)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Hikma Farmaceutica</td>
<td class="formItem"></td>
<td class="formItem">452742943</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b432696a-f12e-4fd8-8385-d77613bb8c72</div>
<div>Set id: 6a4a2afa-4f00-41d4-bd6d-baa0a95f6929</div>
<div>Version: 2</div>
<div>Effective Time: 20100315</div>
</div>
</div>Â <div class="DistributorName">West-ward Pharmaceutical Corp</div></p>
</body></html>
